Halozyme Therapeutics, Inc. (HALO)
76.92
-2.59
(-3.26%)
USD |
NASDAQ |
Feb 12, 16:00
76.94
+0.02
(+0.03%)
After-Hours: 20:00
Halozyme Therapeutics EPS Diluted (Quarterly) : 1.432 for Sept. 30, 2025
EPS Diluted (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| Johnson & Johnson | 2.098 |
| Merck & Co., Inc. | 1.191 |
| AIM ImmunoTech, Inc. | -1.567 |
| Stryker Corp. | 2.20 |
| Skye Bioscience, Inc. | -0.3216 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | 175.22M |
| Revenue (Quarterly) | 354.26M |
| Total Expenses (Quarterly) | 179.04M |
| Enterprise Value | 10.16B |
| Gross Profit Margin (Quarterly) | 79.39% |
| Profit Margin (Quarterly) | 49.46% |
| Earnings Yield | 6.18% |
| Operating Earnings Yield | 7.64% |
| Normalized Earnings Yield | 6.185 |